AR077765A1 - Inhibidores de los virus flaviviridae - Google Patents

Inhibidores de los virus flaviviridae

Info

Publication number
AR077765A1
AR077765A1 ARP100102629A ARP100102629A AR077765A1 AR 077765 A1 AR077765 A1 AR 077765A1 AR P100102629 A ARP100102629 A AR P100102629A AR P100102629 A ARP100102629 A AR P100102629A AR 077765 A1 AR077765 A1 AR 077765A1
Authority
AR
Argentina
Prior art keywords
flaviviridae virus
virus inhibitors
compounds
infections
flaviviridae
Prior art date
Application number
ARP100102629A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR077765A1 publication Critical patent/AR077765A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se proporcionan los compuestos de la Formula 1: y sus sales farmacéuticamente aceptables y ésteres. Los compuestos, composiciones y métodos proporcionados resultan de utilidad en el tratamiento de infecciones por el virus Flaviviridae, particularmente las infecciones de la hepatitis C.
ARP100102629A 2009-07-21 2010-07-19 Inhibidores de los virus flaviviridae AR077765A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22736709P 2009-07-21 2009-07-21
US24091109P 2009-09-09 2009-09-09
US35946610P 2010-06-29 2010-06-29

Publications (1)

Publication Number Publication Date
AR077765A1 true AR077765A1 (es) 2011-09-21

Family

ID=42711860

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102629A AR077765A1 (es) 2009-07-21 2010-07-19 Inhibidores de los virus flaviviridae

Country Status (26)

Country Link
US (2) US8569302B2 (es)
EP (1) EP2475657B1 (es)
JP (2) JP5841531B2 (es)
KR (1) KR20120051022A (es)
CN (1) CN102471327A (es)
AP (1) AP3409A (es)
AR (1) AR077765A1 (es)
AU (1) AU2010276441B2 (es)
CA (1) CA2767088C (es)
CL (1) CL2012000147A1 (es)
CO (1) CO6491049A2 (es)
CR (1) CR20120081A (es)
DK (1) DK2475657T3 (es)
EA (1) EA020816B1 (es)
EC (1) ECSP12011684A (es)
ES (1) ES2427342T3 (es)
HK (1) HK1166788A1 (es)
IL (1) IL217243A (es)
MX (1) MX2012000959A (es)
NZ (1) NZ597528A (es)
PE (1) PE20120666A1 (es)
SG (1) SG177709A1 (es)
TW (1) TW201116525A (es)
UY (1) UY32793A (es)
WO (1) WO2011011303A1 (es)
ZA (1) ZA201200940B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201116525A (en) * 2009-07-21 2011-05-16 Gilead Sciences Inc Inhibitors of flaviviridae viruses
PT2507249E (pt) 2009-09-09 2016-02-15 Gilead Sciences Inc Inibidores de vírus flaviviridae
BR112012006180A2 (pt) 2009-09-21 2015-09-08 Gilead Sciences Inc processos e intermediários para a preparação de análogos de 1'-substituido carba-nucleosídeo
ES2543105T3 (es) * 2010-01-15 2015-08-14 Gilead Sciences, Inc. Inhibidores de virus flaviviridae
AU2011205744B2 (en) * 2010-01-15 2015-06-25 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
MX2012014918A (es) * 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
SG187561A1 (en) 2010-07-22 2013-03-28 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
ES2561888T3 (es) 2011-07-13 2016-03-01 Gilead Sciences, Inc. Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae
ME02590B (me) 2012-06-26 2017-06-20 Bayer Pharma AG N- [4-(hinolin-4-iloksi)cikloheksil(metil)] (hetero)arilkarboksamidi kao antagonisti androgenog receptora, njihova proizvodnja i upotreba kao medicinski produkti
US8759544B2 (en) * 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
CN102964295B (zh) * 2012-12-17 2014-08-20 寿光富康制药有限公司 一种2-取代-4-(哌啶基甲基)吡啶的制备方法
EP2762124A1 (en) * 2013-01-31 2014-08-06 IP Gesellschaft für Management mbH Packaging comprising administration units of polymorphs, amorphous forms or solvates
US9492438B2 (en) * 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
AU2015370004B2 (en) 2014-12-26 2021-03-11 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MX2018003161A (es) 2015-09-16 2018-05-17 Gilead Sciences Inc Metodos para tratar infecciones por virus arenaviridae y coronaviridae.
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017210489A1 (en) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. Compounds
TW201836615A (zh) 2017-03-14 2018-10-16 美商基利科學股份有限公司 治療貓冠狀病毒感染之方法
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EP4096678A1 (en) 2020-01-27 2022-12-07 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
WO2021262826A2 (en) 2020-06-24 2021-12-30 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
PE20231983A1 (es) 2020-08-27 2023-12-12 Gilead Sciences Inc Compuestos y metodos para el tratamiento de infecciones virales
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
EP4320128A1 (en) 2022-03-02 2024-02-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861421A (en) 1995-12-21 1999-01-19 Smithkline Beecham Corporation 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds
US20050119332A1 (en) 1998-03-12 2005-06-02 Lone Jeppesen Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
US20020002199A1 (en) 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
EP1395571A1 (en) 2001-06-11 2004-03-10 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AP1753A (en) 2001-06-11 2007-07-18 Shire Biochem Inc Thiophene derivatives as antiviral agents for flavvivirus infection
BR0316771A (pt) 2002-12-10 2005-10-25 Virochem Pharma Inc Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
PT1569929E (pt) 2002-12-10 2010-06-18 Virochem Pharma Inc Compostos e métodos para o tratamento ou prevenção de infecções por flavivírus
DE10359791A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
US7521473B2 (en) 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
US7470701B2 (en) * 2004-03-30 2008-12-30 Novartis Vaccines And Diagnostics, Inc. Substituted 2,5-heterocyclic derivatives
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
DE102004061746A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
SG161315A1 (en) * 2005-05-13 2010-05-27 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
CA2636879A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
EP2104674B8 (en) * 2006-11-15 2013-10-02 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections
ATE524465T1 (de) 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
MX2011005896A (es) 2008-12-03 2011-09-29 Presidio Pharmaceuticals Inc Inhibidores de hcv ns5a.
TW201116525A (en) * 2009-07-21 2011-05-16 Gilead Sciences Inc Inhibitors of flaviviridae viruses
PT2507249E (pt) 2009-09-09 2016-02-15 Gilead Sciences Inc Inibidores de vírus flaviviridae
MX2012006026A (es) 2009-11-25 2012-08-15 Vertex Pharma Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
ES2543105T3 (es) 2010-01-15 2015-08-14 Gilead Sciences, Inc. Inhibidores de virus flaviviridae
AU2011205744B2 (en) * 2010-01-15 2015-06-25 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.

Also Published As

Publication number Publication date
DK2475657T3 (da) 2013-09-23
HK1166788A1 (es) 2012-11-09
JP2015205940A (ja) 2015-11-19
TW201116525A (en) 2011-05-16
UY32793A (es) 2011-01-31
CA2767088C (en) 2018-07-10
CO6491049A2 (es) 2012-07-31
AP3409A (en) 2015-08-31
ZA201200940B (en) 2014-07-30
ECSP12011684A (es) 2012-04-30
CL2012000147A1 (es) 2012-09-07
NZ597528A (en) 2014-08-29
JP2012533630A (ja) 2012-12-27
US20110020278A1 (en) 2011-01-27
IL217243A0 (en) 2012-02-29
EA020816B1 (ru) 2015-01-30
PE20120666A1 (es) 2012-06-01
EA201290053A1 (ru) 2012-07-30
CA2767088A1 (en) 2011-01-27
EP2475657B1 (en) 2013-06-12
ES2427342T3 (es) 2013-10-30
AU2010276441B2 (en) 2015-07-02
CR20120081A (es) 2012-07-04
SG177709A1 (en) 2012-02-28
JP5841531B2 (ja) 2016-01-13
AU2010276441A1 (en) 2012-02-02
EP2475657A1 (en) 2012-07-18
AP2012006085A0 (en) 2012-02-29
US8569302B2 (en) 2013-10-29
IL217243A (en) 2014-07-31
WO2011011303A1 (en) 2011-01-27
KR20120051022A (ko) 2012-05-21
US20140030223A1 (en) 2014-01-30
MX2012000959A (es) 2012-03-06
CN102471327A (zh) 2012-05-23

Similar Documents

Publication Publication Date Title
AR077765A1 (es) Inhibidores de los virus flaviviridae
ECSP12012104A (es) Inhibidores de virus flaviviridae
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CR20120418A (es) Inhibidores de virus flaviviridae
ECSP15000435A (es) Inhibidores macrocíclicos de virus flaviviridae
CO7240410A2 (es) Inhibidores macrocíclicos de virus flaviviridae
EA201492205A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
EA201492209A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
CO6460766A2 (es) Compuestos de haloalquil heteroaril benzamida
CO7160104A2 (es) Inhibidores de virus de hepatitis c
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
IN2012DN01855A (es)
UY30500A1 (es) Compuestos de azabencimidazolilo
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
ECSP099319A (es) Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CR20110605A (es) Compuestos heterocíclicos antivirales
UY34066A (es) Inhibidores del virus de la hepatitis c
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
SV2011003796A (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
ECSP13013075A (es) Método de tratamiento de la fiebre dengue
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
UY32247A (es) Nuevos compuestos de aminociclohexilo, composiciones farmacéuticas de los mismos y aplicaciones
UA107801C2 (en) Derivatives of thiophene-2-carboxylic acid inhibitors viruses flaviviridae

Legal Events

Date Code Title Description
FB Suspension of granting procedure